Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $3.4 million.

  • Enanta Pharmaceuticals' Other Non-Current Assets changed 0.0% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $3.4 million for FY2025, which is 0.0% changed from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Other Non-Current Assets stood at $3.4 million, which was down 0.0% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Other Non-Current Assets ranged from a high of $4.0 million in Q2 2022 and a low of $608000.0 during Q1 2021
  • Moreover, its 5-year median value for Other Non-Current Assets was $3.4 million (2024), whereas its average is $2.9 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Other Non-Current Assets soared by 55263.16% in 2022, and later crashed by 1532.26% in 2024.
  • Enanta Pharmaceuticals' Other Non-Current Assets (Quarter) stood at $608000.0 in 2021, then surged by 552.63% to $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then dropped by 15.32% to $3.4 million in 2024, then changed by 0.0% to $3.4 million in 2025.
  • Its Other Non-Current Assets stands at $3.4 million for Q3 2025, versus $3.4 million for Q2 2025 and $3.4 million for Q1 2025.